U
SVA

UBS’s Sinovac Biotech, Ltd SVA Stock Holding History

UBS’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,000
Closed -$6K – 11467
2014
Q2 		$6K Buy
1,000
+500
+100% +$3.04K ﹤0.01% 9466
2014
Q1 		$4K Buy
+500
New +$3.31K ﹤0.01% 9801

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS's SVA Position: Q3 2014 in Review

UBS increased its Sinovac Biotech, Ltd (SVA) stake by 21% in Q3 2014, buying an estimated $6.01K and bringing the position to 6,509 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #7458.

UBS first reported a position in SVA in Q2 2013 and has held it in 5 quarters since. The position peaked at $45K in Q4 2013. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • UBS held 6,509 shares of Sinovac Biotech, Ltd worth $31K as of Q3 2014.
  • UBS bought 1,120 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $6.01K.
  • Sinovac Biotech, Ltd made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7458 holding.
  • UBS first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 5 quarters since.
  • UBS's Sinovac Biotech, Ltd position peaked at $45K in Q4 2013.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.